** Sage Therapeutics' shares fall 5.5% to $6.87 in morning trade
** Co says it will lay off more than 165 employees, including more than half of its R&D team, as part of reorganization plan
** To prioritize launch of postpartum depression pill Zurzuvae, which has been jointly developed with Biogen , and early-stage experimental drugs
** Last week, co said it would stop developing its experimental drug dalzanemdor, for Alzheimer's disease after it failed to meet main goal in late-stage trial
** Avg recommendation of 19 brokerages is a "hold;" median PT is $10 - LSEG
** As of last close, stock had slumped 66.5% YTD vs 11% increase in Nasdaq Biotechnology index
(Reporting by Leroy Leo in Bengaluru)
((Leroy.Dsouza@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.